EFHD1

Across TCGA pan-cancer cohorts, EFHD1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EFHD1 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EFHD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EFHD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where EFHD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.592	0.284	.012	13	view →
PDAC	OS	Median	III,IV	0.566	0.313	.015	12	view →
LUAD	OS	Tertile	III,IV	0.842	0.484	.016	10	view →
GBM	OS	Quartile	All	0.298	0.637	.036	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EFHD1–CCRCC (DFS)

Open the CCRCC breakdown →